Cargando…
Safety of biweekly α(1)-antitrypsin treatment in the RAPID programme
Administration of 120 mg·kg(−1) α(1)-antitrypsin on a biweekly basis was safe and well tolerated http://ow.ly/CVbz30lUBum
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Respiratory Society
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557539/ https://www.ncbi.nlm.nih.gov/pubmed/30237305 http://dx.doi.org/10.1183/13993003.00897-2018 |
| _version_ | 1783425466832519168 |
|---|---|
| author | Greulich, Timm Chlumsky, Jan Wencker, Marion Vit, Oliver Fries, Michael Chung, Thomas Shebl, Amgad Vogelmeier, Claus Chapman, Kenneth R. McElvaney, Noel G. |
| author_facet | Greulich, Timm Chlumsky, Jan Wencker, Marion Vit, Oliver Fries, Michael Chung, Thomas Shebl, Amgad Vogelmeier, Claus Chapman, Kenneth R. McElvaney, Noel G. |
| author_sort | Greulich, Timm |
| collection | PubMed |
| description | Administration of 120 mg·kg(−1) α(1)-antitrypsin on a biweekly basis was safe and well tolerated http://ow.ly/CVbz30lUBum |
| format | Online Article Text |
| id | pubmed-6557539 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | European Respiratory Society |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-65575392019-06-13 Safety of biweekly α(1)-antitrypsin treatment in the RAPID programme Greulich, Timm Chlumsky, Jan Wencker, Marion Vit, Oliver Fries, Michael Chung, Thomas Shebl, Amgad Vogelmeier, Claus Chapman, Kenneth R. McElvaney, Noel G. Eur Respir J Agora Administration of 120 mg·kg(−1) α(1)-antitrypsin on a biweekly basis was safe and well tolerated http://ow.ly/CVbz30lUBum European Respiratory Society 2018-11-29 /pmc/articles/PMC6557539/ /pubmed/30237305 http://dx.doi.org/10.1183/13993003.00897-2018 Text en Copyright ©ERS 2018 http://creativecommons.org/licenses/by-nc/4.0/ This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. |
| spellingShingle | Agora Greulich, Timm Chlumsky, Jan Wencker, Marion Vit, Oliver Fries, Michael Chung, Thomas Shebl, Amgad Vogelmeier, Claus Chapman, Kenneth R. McElvaney, Noel G. Safety of biweekly α(1)-antitrypsin treatment in the RAPID programme |
| title | Safety of biweekly α(1)-antitrypsin treatment in the RAPID programme |
| title_full | Safety of biweekly α(1)-antitrypsin treatment in the RAPID programme |
| title_fullStr | Safety of biweekly α(1)-antitrypsin treatment in the RAPID programme |
| title_full_unstemmed | Safety of biweekly α(1)-antitrypsin treatment in the RAPID programme |
| title_short | Safety of biweekly α(1)-antitrypsin treatment in the RAPID programme |
| title_sort | safety of biweekly α(1)-antitrypsin treatment in the rapid programme |
| topic | Agora |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557539/ https://www.ncbi.nlm.nih.gov/pubmed/30237305 http://dx.doi.org/10.1183/13993003.00897-2018 |
| work_keys_str_mv | AT greulichtimm safetyofbiweeklya1antitrypsintreatmentintherapidprogramme AT chlumskyjan safetyofbiweeklya1antitrypsintreatmentintherapidprogramme AT wenckermarion safetyofbiweeklya1antitrypsintreatmentintherapidprogramme AT vitoliver safetyofbiweeklya1antitrypsintreatmentintherapidprogramme AT friesmichael safetyofbiweeklya1antitrypsintreatmentintherapidprogramme AT chungthomas safetyofbiweeklya1antitrypsintreatmentintherapidprogramme AT sheblamgad safetyofbiweeklya1antitrypsintreatmentintherapidprogramme AT vogelmeierclaus safetyofbiweeklya1antitrypsintreatmentintherapidprogramme AT chapmankennethr safetyofbiweeklya1antitrypsintreatmentintherapidprogramme AT mcelvaneynoelg safetyofbiweeklya1antitrypsintreatmentintherapidprogramme |